Chongqing Lummy Pharmaceutical Co.,Ltd. Posted 44.7 Million Yuan Net Loss in First Three Quarters of 2022

Chongqing Lummy Pharmaceutical Co.,Ltd. (重庆莱美药业股份有限公司) (300006.SZ) reported a net loss of 44.7 million yuan in the first three quarters of 2022, reversing a net profit of 17 million yuan for the same period in the previous year.

Meanwhile, the company posted 670.9 million yuan in revenue, down 24.8% year-on-year.

At the end of the reporting period, it had 3 billion yuan in total assets and 833.3 million yuan in total liabilities, with a liability-to-asset ratio of 27.4%.